ReviewBioResearch open access2016
Microbiota and Neurological Disorders: A Gut Feeling.
Review in BioResearch open access, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 147 citations in OpenAlex.
- Evaluation of periodontal status in gastritis patients with clinical and microbiological parameters.BMC oral health · 2026Observational
- Gut microbiome- targeted intervention ameliorates structural and transcriptomic changes in the kidney of hindlimb unloaded mouse model.Animal microbiome · 2026Article
- The gut-eye axis in age-related macular degeneration: from microbial dysbiosis to targeted intervention strategies.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Article
- A comprehensive review on potential role of selenium, selenoproteins and selenium nanoparticles in male fertility.Heliyon · 2024Review
- Pathophysiology of acute lung injury in patients with acute brain injury: the triple-hit hypothesis.Critical care (London, England) · 2024Review
- Additive or Interactive Associations of Food Allergies with Glutathione S-Transferase Genes in Relation to ASD and ASD Severity in Jamaican Children.Journal of autism and developmental disorders · 2024Article
- The interplay between mitochondria, the gut microbiome and metabolites and their therapeutic potential in primary mitochondrial disease.Frontiers in pharmacology · 2024Review
- Twnbiome: a public database of the healthy Taiwanese gut microbiome.BMC bioinformatics · 2023Article
- Characterization of markers, functional properties, and microbiome composition in human gut-derived bacterial extracellular vesicles.Gut microbes · 2023Article
- Influence of food-derived bioactives on gut microbiota compositions and their metabolites by focusing on neurotransmitters.Food science and biotechnology · 2023Review
- Understanding the ADHD-Gut Axis by Metabolic Network Analysis.Metabolites · 2023Article
- Ruminococcus gnavus: friend or foe for human health.FEMS microbiology reviews · 2023Review
- Moderating Gut Microbiome/Mitochondrial Axis in Oxazolone Induced Ulcerative Colitis: The Evolving Role of β-Glucan and/or, Aldose Reductase Inhibitor, Fidarestat.International journal of molecular sciences · 2023Article
- Modulating gut dysbiosis and mitochondrial dysfunction in oxazolone-induced ulcerative colitis: the restorative effects of β-glucan and/or celastrol.Redox report : communications in free radical research · 2022Article
- The Role of Microbiome in Brain Development and Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2022Review
- Selenium supplementation influences mice testicular selenoproteins driven by gut microbiota.Scientific reports · 2022Article
- A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.Clinical microbiology reviews · 2022Review
- Cecal Metabolomic Fingerprint of Unscathed Rats: Does It Reflect the Good Response to a Provocative Decompression?Frontiers in physiology · 2022Article
- Fecal metabolomic profiles: A comparative study of patients with colorectal cancerWorld journal of gastroenterology · 2021Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host-microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.